Agios Pharmaceuticals price target lowered to $54 from $55 at BofA
BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ ...
Bank of America Securities Keeps Their Buy Rating on Agios Pharma (AGIO)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Agios Pharma (AGIO – Research Report), ...
Agios Pharmaceuticals principal accounting officer sells shares for $78,134
Theodore James Jr. Washburn, the Principal Accounting Officer at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold 2,272 shares of common stock. The shares were sold at a price of $34.39 each, ...